Last updated on February 2012

A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia

Brief description of study

Hypothesis; That inhibition of plasma Blys by the monoclonal antibody Belimumab will reduce both the survival of the lymphoplasmacytoid cells of Waldenstrom Macroglobulinaemia (WM), and their production of monoclonal IgM, resulting in a reduction of IgM paraprotein.

Clinical Study Identifier: NCT01142011

Find a site near you

Start Over

The Peter MacCallum Cancer Centre

Melbourne, Australia
  Connect »

Alfred Health

Melbourne, Australia
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.